Compare TGS & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TGS | TLX |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | Argentina | Australia |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.3B |
| IPO Year | N/A | N/A |
| Metric | TGS | TLX |
|---|---|---|
| Price | $31.40 | $9.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $40.00 | $21.00 |
| AVG Volume (30 Days) | ★ 198.3K | 95.0K |
| Earning Date | 11-05-2025 | 01-01-0001 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | ★ 40.85 | N/A |
| EPS | ★ 0.34 | 0.04 |
| Revenue | ★ $958,309,826.00 | $664,225,558.00 |
| Revenue This Year | $47.07 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $19.30 | $225.26 |
| Revenue Growth | N/A | ★ 55.35 |
| 52 Week Low | $19.74 | $8.76 |
| 52 Week High | $34.37 | $30.36 |
| Indicator | TGS | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 58.47 | 46.99 |
| Support Level | $30.95 | $9.37 |
| Resistance Level | $33.00 | $9.93 |
| Average True Range (ATR) | 1.26 | 0.23 |
| MACD | -0.10 | 0.06 |
| Stochastic Oscillator | 64.29 | 69.14 |
Transportadora de Gas del Sur SA is a transporters of natural gas in Latin America. The company's operating segments include Natural Gas Transportation, Midstream, Telecommunications, Production and Commercialization Liquids, Other Services, and Telecommunications. It generates maximum revenue from the Production and Commercialization of the Liquids segment. Geographically, it derives the majority of its revenue from Argentina.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.